Advanced Drug Delivery Reviews - Upcoming special issue

Advanced Drug Delivery Reviews - Upcoming special issue
Protein Engineering and Drug Delivery - Introduction from the Editor

In 2008, the editorial team of Advanced Drug Delivery Reviews (ADDR), once again, dedicated itself to making ADDR the best it could be. Our benchmark was not only further gain in the impact factor year after year, but also the journal’s long term success in defining the future direction of drug delivery as a driver in transforming therapeutics. To accelerate our pace towards that goal, the team acted on its well-proven practice of selecting timely topics, recruiting rising stars to serve as theme editors, and giving them the intellectual freedom to create their master piece.

Dr. Julio A. Camarero, Associate Professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California, exemplifies the caliber we look for in theme editors. Dr. Camarero’s theme issue, scheduled for the latter part of 2009, will be on the most recent advances in the field of protein engineering for fulfilling the promise of proteins and peptides in therapeutics, drug discovery and delivery. According to Dr. Camarero, while peptides, proteins and monoclonal antibodies have demonstrated their important role in revolutionizing therapeutics, substantial optimization and engineering of the lead molecule is often required to achieve the appropriate stability, improved pharmacokinetic/pharmacodynamic performance, low immunogenicity and compatibility with a commercially viable development path. This, in turn, may require the concurrent development of novel formulations or alternative delivery strategies for patient convenience.

Overall, nanobiotechnology is the unifying theme of the 15 issues of ADDR in 2008. The top 15 most cited articles, comprising 10% of the total number of articles, illustrates the breadth of ingenious ways that can result from the convergence of nanotechnology and biotechnology in revolutionizing therapeutics. These articles are listed below.

In planning for future issues, the editorial team is mindful that biomaterials are the core of drug delivery. ADDR will continue to build on this strength and point the way to how advances in genomics and stem cell biology can be harnessed to expand the reach of biomaterials in therapeutics at the molecular level. Please email Vincent H.L. Lee, Editor-in-Chief, if you would like to organize a theme issue on topics within this context.

Visit the new Pharmaceutical Sciences home on Elsevier.com

Top 15 Most Highly Cited Articles in ADDR in 2008

1. Ma PX. Biomimetic materials for tissue engineering. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(2):184-98. Available from: www.scopus.com.

2. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(4-5):517-29. Available from: www.scopus.com.

3. Matsumoto M, Seya T. TLR3: Interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(7):805-12. Available from: www.scopus.com.

4. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(4-5):548-58. Available from: www.scopus.com.

5. Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology - towards biomedical applications. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(3):299-327. Available from: www.scopus.com.

6. Chung C, Burdick JA. Engineering cartilage tissue. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(2):243-62. Available from: www.scopus.com.

7. Hwang NS, Varghese S, Elisseeff J. Controlled differentiation of stem cells. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(2):199-214. Available from: www.scopus.com.

8. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(9):1037-55. Available from: www.scopus.com.

9. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(1):59-68. Available from: www.scopus.com.

10. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(12):1329-46. Available from: www.scopus.com.

11. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(8):863-75. Available from: www.scopus.com.

12. Yoneyama M, Onomoto K, Fujita T. Cytoplasmic recognition of RNA. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(7):841-6. Available from: www.scopus.com

13. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(6):673-91. Available from: www.scopus.com.

14. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(4-5):452-72. Available from: www.scopus.com.

15. Brocchini S, Godwin A, Balan S, Choi J-, Zloh M, Shaunak S. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev. 2008 [cited 2009 Apr 10];60(1):3-12. Available from: www.scopus.com.